United European Gastroenterology Week | 2026

Lilly’s Omvoh Shows Broad One-Year Disease Control in Ulcerative Colitis and Crohn’s Disease

New analyses from Eli Lilly suggest that patients with moderate to severe ulcerative colitis or Crohn’s disease treated with Omvoh, also known as mirikizumab, were able to meet several measures of disease control at the same time after one year of treatment.

What the New Analyses Measured

In ulcerative colitis, Lilly assessed a composite goal called comprehensive disease control. A patient needed to have clinical remission, histologic remission, faecal calprotectin of 250 micrograms per gram or lower, and no corticosteroid use for at least 12 weeks before week 52.

For Crohn’s disease, the company evaluated corticosteroid-free deep remission. This required clinical remission based on the Crohn’s Disease Activity Index, endoscopic remission, and avoidance of corticosteroids for at least 12 weeks before week 52.[lilly]

The analyses also examined whether patients who reached these broader outcomes reported better daily functioning and health-related quality of life using the Inflammatory Bowel Disease Questionnaire.

Ulcerative Colitis Results

The ulcerative colitis analysis included patients who responded to Omvoh during the LUCENT-1 induction study and were then reassigned in LUCENT-2 to either continue Omvoh or switch to placebo. More than one third of participants had previously not benefited from a biologic medicine.

At one year, 27.7 percent of patients continuing Omvoh achieved comprehensive disease control, compared with 14 percent of those receiving placebo. Among patients with earlier biologic failure, the rates were 23.4 percent with Omvoh and 9.4 percent with placebo.

Quality-of-life findings were also notable. Among Omvoh-treated patients who achieved comprehensive disease control, 91.1 percent also reached remission on the IBD questionnaire, compared with 65.2 percent of those who did not reach the composite outcome.

Crohn’s Disease Results

In the VIVID-1 Crohn’s disease study, nearly half of participants had previously experienced failure with a biologic treatment. At one year, 20.4 percent of Omvoh-treated patients achieved corticosteroid-free deep remission, compared with 2 percent of placebo recipients.

Among patients with prior biologic failure, 15.7 percent treated with Omvoh achieved the composite outcome, while no placebo-treated patients did. In addition, 88.1 percent of Omvoh-treated patients who achieved deep remission also reported IBD questionnaire remission, compared with 51 percent of those who did not achieve deep remission.

Safety Profile

Lilly said the safety observations from the LUCENT and VIVID programmes had been reported earlier.

Regulatory and Development Context

Omvoh is approved for adults with moderately to severely active ulcerative colitis and Crohn’s disease in 47 countries. It is also approved as a single-injection maintenance regimen for ulcerative colitis in several markets, including the United States, European Union, Canada and Japan.